DLK1 and neoplasm: Similar to effects observed with MC38, αDC1-DLK1 vaccination led to significant size reductions in LLC tumor lesions (Supplementary Figure 7A) that were also deficient in CD31+ vessels by IHC and qPCR when compared to control treated cohorts (Supplementary Figure 7B).